NCT01719211

Brief Summary

The investigators have successfully identified two novel genetic loci for MVP on chromosomes 11 and 13 and are searching for altered genes in these regions. This requires recruiting large families who may have MVP linked to these or other chromosomes; and obtaining DNA samples from 1,000-1,500 individually affected patients to study the relation between DNA markers throughout the genome and MVP. It is our expectation that the results of this study will lead to the discovery of gene(s) responsible for MVP. This will lead to improved understanding of the disease and, in turn, improved ability to treat and prevent progression in genetically susceptible individuals.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 1999

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 1999

Completed
13.8 years until next milestone

First Submitted

Initial submission to the registry

October 30, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 1, 2012

Completed
13.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

November 8, 2023

Status Verified

November 1, 2023

Enrollment Period

26.9 years

First QC Date

October 30, 2012

Last Update Submit

November 7, 2023

Conditions

Mitral Valve Prolapse

Keywords

MVP, mitral valve

Outcome Measures

Primary Outcomes (1)

  • Discovery of the genetic basis of Mitral Valve Prolapse

    Genome-wide association

    5 years

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients referred for 2D echo for MVP

You may qualify if:

  • Mitral valve prolapse

You may not qualify if:

  • Other mitral valve diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mass General Hospital

Boston, Massachusetts, 02114, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

DNA

MeSH Terms

Conditions

Mitral Valve Prolapse

Condition Hierarchy (Ancestors)

Heart Valve ProlapseHeart Valve DiseasesHeart DiseasesCardiovascular Diseases

Study Officials

  • robert a levine, MD

    Massachusetts General Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Susan Slaugenhaupt, PhD

CONTACT

6176433217slaugenhaupt@chgr.mgh.harvard.edu

Robert a levine, MD

CONTACT

6177241995rlevine@partners.org

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Cardiologist

Study Record Dates

First Submitted

October 30, 2012

First Posted

November 1, 2012

Study Start

January 1, 1999

Primary Completion

December 1, 2025

Study Completion

December 1, 2025

Last Updated

November 8, 2023

Record last verified: 2023-11

Locations

US(1)